Publication: Mice immunized with the vaccine candidate hexapro spike produce neutralizing antibodies against sars-cov-2
4
Issued Date
2021-01-01
Resource Type
ISSN
2076393X
Other identifier(s)
2-s2.0-85106581667
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Vaccines. Vol.9, No.5 (2021)
Suggested Citation
Chotiwat Seephetdee, Nattawut Buasri, Kanit Bhukhai, Kitima Srisanga, Suwimon Manopwisedjaroen, Sarat Lertjintanakit, Nut Phueakphud, Chatbenja Pakiranay, Niwat Kangwanrangsan, Sirawat Srichatrapimuk, Suppachok Kirdlarp, Somnuek Sungkanuparph, Somchai Chutipongtanate, Arunee Thitithanyanont, Suradej Hongeng, Patompon Wongtrakoongate Mice immunized with the vaccine candidate hexapro spike produce neutralizing antibodies against sars-cov-2. Vaccines. Vol.9, No.5 (2021). doi:10.3390/vaccines9050498 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/77355
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Mice immunized with the vaccine candidate hexapro spike produce neutralizing antibodies against sars-cov-2
Author(s)
Chotiwat Seephetdee
Nattawut Buasri
Kanit Bhukhai
Kitima Srisanga
Suwimon Manopwisedjaroen
Sarat Lertjintanakit
Nut Phueakphud
Chatbenja Pakiranay
Niwat Kangwanrangsan
Sirawat Srichatrapimuk
Suppachok Kirdlarp
Somnuek Sungkanuparph
Somchai Chutipongtanate
Arunee Thitithanyanont
Suradej Hongeng
Patompon Wongtrakoongate
Nattawut Buasri
Kanit Bhukhai
Kitima Srisanga
Suwimon Manopwisedjaroen
Sarat Lertjintanakit
Nut Phueakphud
Chatbenja Pakiranay
Niwat Kangwanrangsan
Sirawat Srichatrapimuk
Suppachok Kirdlarp
Somnuek Sungkanuparph
Somchai Chutipongtanate
Arunee Thitithanyanont
Suradej Hongeng
Patompon Wongtrakoongate
Other Contributor(s)
Abstract
Updated and revised versions of COVID-19 vaccines are vital due to genetic variations of the SARS-CoV-2 spike antigen. Furthermore, vaccines that are safe, cost-effective, and logistic-friendly are critically needed for global equity, especially for middle-to low-income countries. Recombinant protein-based subunit vaccines against SARS-CoV-2 have been reported using the receptor-binding domain (RBD) and the prefusion spike trimers (S-2P). Recently, a new version of prefusion spike trimers, named HexaPro, has been shown to possess two RBD in the “up” conformation, due to its physical property, as opposed to just one exposed RBD found in S-2P. Importantly, this HexaPro spike antigen is more stable than S-2P, raising its feasibility for global logistics and supply chain. Here, we report that the spike protein HexaPro offers a promising candidate for the SARS-CoV-2 vaccine. Mice immunized by the recombinant HexaPro adjuvanted with aluminum hydroxide using a prime-boost regimen produced high-titer neutralizing antibodies for up to 56 days after initial immunization against live SARS-CoV-2 infection. Also, the level of neutralization activity is comparable to that of convalescence sera. Our results indicate that the HexaPro subunit vaccine confers neutralization activity in sera collected from mice receiving the prime-boost regimen.